Medical devices, healthcare technology and the business of care
510(k) clearance · K262276

Cyperus

Contrario Medical, Inc. · Decision date Oct 26, 2026

MEDTECHLEDGER EXPLANATIONK262276

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for Cyperus, a 510(k) submitted by Contrario Medical, Inc. of Houston, Texas, under number K262276. The decision date is 26 October 2026 and the application was received 6 July 2026. The device is classified as labware for assisted reproduction under regulation 21 CFR 884.6160, product code MQK, in the Obstetrics/Gynecology specialty and review panel. The record lists a traditional summary, no third-party review, no combination product status and no authorized predetermined change control plan.

SESE in the 510(k) pathway means the device was cleared as substantially equivalent to a predicate; it is not a premarket approval. The public record does not describe Cyperus's components, materials, intended use, predicate device or performance data, and no summary statement is included in the public information. The RSS listing confirms the same clearance and applicant. Whether the device is a new instrument or a modification of an existing product cannot be determined from these fields.

Readers should treat the clearance as a regulatory status only. No clinical, safety or comparative performance conclusions follow from the record, and the basis for the equivalence determination remains in FDA's underlying review documents, which were not provided here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Obstetrics/Gynecology
Decision date
Oct 26, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262276
Regulatory pathway
510(k) premarket notification
Product code
MQK
Decision code
SESE
Decision date
Oct 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Labware, Assisted Reproduction.

Product code
MQK
FDA device class
2

FDA decision timeline

  1. K262276 received

    Application receipt date recorded by FDA.

  2. K262276 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code MQK

Product / regulatory recordCompanyPathwayDecision dateSource
My123Baby Medical Limited Dba Boost Fertility510(k) clearanceOct 30, 2026FDA
Fertilis Pty, Ltd.510(k) clearanceOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Contrario Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Houston, TX

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records